Clinical

Latest News


Latest Videos


CME Content


More News

Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.

Dr Ian Riddock explains the patient journey post-myocardial infarction (MI), from hospital to outpatient care.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.

Screenshot of Marc Bonaca, MD, MPH, of the University of Colorado School of Medicine

Patients often have comorbidities that make it important to consider them holistically and not bucket them into one disease state, and the findings on rivaroxaban show broad benefits and a favorable risk-benefit profile, said Marc Bonaca, MD, MPH, of CPC Clinical Research and CPC Community Health and the University of Colorado School of Medicine.

Thumbnail of Raul Santos, MD, PhD, of University of São Paulo Medical School

Treating children with familial hypercholesterolemia (FH) early can help reduce progression of atherosclerosis without adverse events related to growth and development, said Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute, and associate professor, University of São Paulo Medical School, Brazil.

Pam Taub, MD

There is some confusion about the differences between the European and American guidelines on lowering low-density lipoprotein (LDL) cholesterol, but it’s clear that lower is better, said Pam Taub, MD, FACC, professor of medicine, Division of Cardiovascular Medicine, UC San Diego School of Medicine.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo